Recent Updates
Recently added Catalysts
OM Negative Sentiment Score: 25/100

Outset Medical, Inc. (OM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: Bronstein, Gewirtz & Grossman, LLC is investigating potential claims related to Outset Medical, Inc. after the company reported second quarter financial results that significantly missed consensus estimates and lowered its full year outlook. This disappointing financial performance led to shares of Outset falling by 68.53% in a single day. Investors are encouraged to participate in the investigation, and the firm is representing them on a contingency basis. The investigation aims to uncover any potential wrongdoings that may have affected stock performance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Outset Medical missed consensus estimates by a significant margin.
  • The company lowered its full year 2024 outlook.
  • Shares of Outset fell by 68.53% after the financial results.
  • The investigation suggests potential wrongdoing that could impact investor confidence.

Full Press Release Details

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Outset Medical, Inc. (“Outset” or “the Company”) (NASDAQ: OM). Investors who purchased Outset securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/OM.
Investigation Details
On August 7, 2024, Outset released its second quarter 2024 financial results. The Company missed consensus estimates by a considerable margin and lowered its full year 2024 outlook. According to the Company, the “changes [it] needs to make are entirely in [its] control” and will involve “shifts and adjustments” to its sales team and processes. Based on this news, shares of Outset fell by 68.53% on August 8, 2024.
If you are aware of any facts relating to this investigation or purchased Outset securities, you can assist this investigation by visiting the firm’s site: bgandg.com/OM. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the investigation about Outset Medical, Inc.?

The investigation concerns potential claims from investors after Outset missed financial estimates and lowered its 2024 outlook.

Why did Outset's shares fall recently?

Outset's shares dropped by 68.53% due to disappointing Q2 results and lowered financial forecasts.

How can investors assist in the investigation?

Investors can help by visiting bgandg.com/OM or contacting Bronstein, Gewirtz & Grossman, LLC.

Is there a cost to participate in the investigation?

No, there is no cost unless the firm successfully recovers funds for investors.

What does Bronstein, Gewirtz & Grossman specialize in?

The firm specializes in securities fraud class actions and has recovered significant funds for investors.

Last updated: Aug 22, 2024